Um zukunftsfähig zu sein, wurde unsere aktuelle Webseite für die neuesten Technologien entwickelt. Daher können bei alten Browsern leider Probleme auftreten.
Damit die neue Börse-Online-Seite richtig funktioniert und Spaß macht, empfehlen wir Ihnen einen dieser aktuellen und kostenlosen Browser herunterzuladen:
Zitat:"..GW Pharmaceuticals to Present at Upcoming Investor Conferences....LONDON and CARLSBAD, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW?s Chief Executive Officer, will present a business update at the following virtual investor conferences:............ CITI?s 15th Annual BioPharma Virtual Conference 2020 on Thursday, September 10th, 2020 at 4:15pm EDT.......... Morgan Stanley Healthcare Conference 2020 on Tuesday, September 15th, 2020 at 4:15pm EDT................. Cantor Global Healthcare Conference 2020 on Thursday, September 17th, 2020 at 2:40pm EDT......." ENDE Zitat Quelle:https://www.stockwatch.com/News/...00901&symbol=GWPH®ion=U
Zitat:"?We are pleased to report strong revenue growth in the 3rd quarter despite the challenges presented by COVID-19. Epidiolex meets a serious unmet need within the field of epilepsy and we expect the product to demonstrate continued strong growth in the months and years ahead. The recent expanded indication for the treatment of seizures associated with TSC has been very well received by patients, clinicians and payers,? stated Justin Gover, GW?s Chief Executive Officer. ?We have also now commenced the pivotal Phase 3 program for nabiximols in the treatment of multiple sclerosis spasticity, which provides multiple opportunities for an NDA submission, including as early as next year. Beyond nabiximols, we are advancing several clinical-stage pipeline candidates, including the recent start of a Phase 2 trial in schizophrenia.?.......
FINANCIAL RESULTS............... Total revenue for the quarter ended September 30, 2020 was $137.1 million compared to $91.0 million for the quarter ended September 30, 2019 Total revenue for the first nine months of 2020 of $378.6 million compared to $202.3 million in the prior year period Net loss for the quarter ended September 30, 2020 was $12.2 million compared to net loss of $13.8 million for the quarter ended September 30, 2019 Cash and cash equivalents at September 30, 2020 were $480.3 million...................OPERATIONAL HIGHLIGHTS.......... ENDE Zitat Source/Quelle:https://www.stockwatch.com/News/...01103&symbol=GWPH®ion=U
Epidiolex (cannabidiol) progress: Total Q3 net product sales of Epidiolex of $132.6 million U.S. commercial update U.S. Epidiolex Q3 net product sales of $121.6 million
Zitat:"...GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW?s Chief Executive Officer, will present a business update and 2021 outlook at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:00 am ET (7:00 am PT). In addition, a Q&A breakout session will immediately follow the presentation at 10:20 am ET (7:20 am PT)...:" ENDE Zitat Quelle:https://www.stockwatch.com/News/...10105&symbol=GWPH®ion=U
unklar wie GW diese Woche gen Nord zieht..... ob es am kommenden Dienstag handfeste News gibt..? und jetzt schon ein paar wenige sich eindecken..... tz tz tz
bei um die $129sollte plus/minus geschlossen sein... altes Gap (ebenfalls in #62 bereits zu sehen) bei $91-96 (als Worst-Case ) neues Gap bei $116-118 (Korrekturziel nach Übertreibung) *Open Gaps
Direction Date range§ up Jan-06-2021 116.37 to 118.99 up Nov-03-2020 91.02 to 96.5 *Year Hi-Lo 143.9999 - 67.98 Quelle:http://www.stockta.com/cgi-bin/...mb=GWPH&cobrand=&mode=stock
Zitat:"Our system?s recommendation today is to STAY LONG. The previous BUY signal was issued on 01/05/2021, 3 days ago, when the stock price was 116.2500.......Candlesticks warned us today to be on alert with a new bearish pattern."
Zitat:" Total preliminary net product sales of approximately $148 million for the fourth quarter and approximately $526 million for the full year - - Total Epidiolex® preliminary net product sales of approximately $144 million for the fourth quarter and approximately $510 million for the full year ? - Pivotal US clinical program for nabiximols in MS spasticity underway. Initial data expected in 2021 -,,, Ende Zitat
Zitat:"...Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares.." Quelle:https://www.stockwatch.com/News/...10203&symbol=GWPH®ion=U
* Deutsche Bank Real-Time Indikationen basieren auf Preisen von der Deutschen Bank emittierten Produkten. Diese Produkte versuchen, den jeweiligen Index 1:1 zu tracken.
Die Preisstellung erfolgt börsentäglich zwischen 09:15 und 17:15.